Gilbert Fuller Sells 1,057 Shares of USANA Health Sciences (NYSE:USNA) Stock

USANA Health Sciences, Inc. (NYSE:USNA) Director Gilbert Fuller sold 1,057 shares of the firm’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $21.48, for a total transaction of $22,704.36. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

USANA Health Sciences Price Performance

Shares of NYSE:USNA traded down $0.70 during trading on Tuesday, hitting $20.55. The company’s stock had a trading volume of 102,228 shares, compared to its average volume of 192,244. The company has a 50-day moving average of $26.57 and a 200-day moving average of $28.82. USANA Health Sciences, Inc. has a 12 month low of $18.69 and a 12 month high of $41.83. The firm has a market cap of $375.49 million, a price-to-earnings ratio of 23.35, a P/E/G ratio of 0.94 and a beta of 0.61.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings data on Thursday, October 9th. The company reported $0.56 earnings per share for the quarter. USANA Health Sciences had a net margin of 1.86% and a return on equity of 6.96%. The firm had revenue of $200.22 million for the quarter. USANA Health Sciences has set its Q3 2025 guidance at -0.150–0.150 EPS. As a group, research analysts anticipate that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

Institutional Trading of USANA Health Sciences

Several institutional investors and hedge funds have recently made changes to their positions in USNA. Teacher Retirement System of Texas bought a new position in USANA Health Sciences in the first quarter worth about $888,000. Principal Financial Group Inc. boosted its position in USANA Health Sciences by 2.7% in the first quarter. Principal Financial Group Inc. now owns 55,076 shares of the company’s stock valued at $1,485,000 after buying an additional 1,473 shares during the last quarter. Pzena Investment Management LLC boosted its position in USANA Health Sciences by 0.7% in the first quarter. Pzena Investment Management LLC now owns 1,095,186 shares of the company’s stock valued at $29,537,000 after buying an additional 8,110 shares during the last quarter. Denali Advisors LLC purchased a new stake in USANA Health Sciences in the first quarter valued at approximately $443,000. Finally, KLP Kapitalforvaltning AS boosted its position in USANA Health Sciences by 373.9% in the 1st quarter. KLP Kapitalforvaltning AS now owns 10,900 shares of the company’s stock worth $294,000 after purchasing an additional 8,600 shares in the last quarter. 54.25% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Wall Street Zen cut shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Zacks Research lowered shares of USANA Health Sciences from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 21st. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of USANA Health Sciences in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, USANA Health Sciences has an average rating of “Reduce” and a consensus price target of $36.00.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.